SuperworthiBio IBIO
- Market cap
- $46.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- Q4 FY26 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- Q4 FY26 missing
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −51.6%
iBio's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $50K | $0 | $0 | $175K | $0 | $200K | $0 | $200K+14% | $100K | $0 | $0 | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $1.6M−37% | $1.5M−45% | $904K−66% | $1.1M−52% | $1.3M−19% | $1.9M+22% | $1.9M+111% | $3.2M+183% | $3.5M+172% | $4.3M+128% | $3.3M+71% | n/a |
| SG&A | $3.5M−30% | $3M−62% | $2.7M−23% | $2.4M−6% | $2.8M−21% | $2.7M−7% | $3M+9% | $2.2M−11% | $2.5M−11% | $5.2M+88% | $5.1M+72% | n/a |
| −$5.1M−33% | −$4.5M−58% | −$3.6M−41% | −$3.4M−31% | −$4.1M−20% | −$4.4M−2% | −$4.9M+35% | −$5.2M+53% | −$6M+45% | −$9.4M+114% | −$8.4M+71% | n/a | |
| Interest expense | $26K | $34K+10% | $52K+49% | $60K+253% | $57K+119% | $57K+68% | $54K+4% | $44K−27% | $36K−37% | $41K−28% | $22K−59% | n/a |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$5.7M−68% | −$8.2M−76% | −$3.2M−57% | −$7.8M+29% | −$4M−31% | −$4.4M−47% | −$4.9M+53% | −$5.2M−34% | −$5.7M+43% | −$9M+106% | −$7.7M+59% | −$10.6M+105% |
| −$4.80−88% | −$4.42−94% | −$0.85−92% | −$0.90−85% | −$0.46−90% | −$0.48−89% | −$0.49−42% | −$0.36−60% | −$0.11−76% | −$0.09−81% | −$0.06−88% | −$0.07−81% | |
| 1.2M+171% | 1.9M+279% | 3.7M+463% | 8.6M+903% | 8.6M+621% | 9.1M+392% | 9.9M+166% | 14.4M+67% | 53M+514% | 99.1M+986% | 119.6M+1113% | 145.5M+910% |
EPS, diluted: 16 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY11 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 274, the two on one basis (x25).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest iBio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IBIOiBio | $46.2M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $69M | 11.1× | 14.5× | 0.4× | −3% | 3.7% |
More on iBio
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .